Relaxin immunoglobulin fusion proteins and methods of use
US12275771B2 · kind B2 · utility
0Cited by
21References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 26, 2021 |
| Grant date | Apr 15, 2025 |
| Priority date | — |
| Expiry date | Aug 26, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are relaxin immunoglobulin fusion proteins useful for the treatment or prevention of a disease or condition in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.